These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 2138329

  • 1. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
    Pöllänen J, Vaheri A, Tapiovaara H, Riley E, Bertram K, Woodrow G, Stephens RW.
    Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
    Keijer J, Linders M, van Zonneveld AJ, Ehrlich HJ, de Boer JP, Pannekoek H.
    Blood; 1991 Jul 15; 78(2):401-9. PubMed ID: 1712649
    [Abstract] [Full Text] [Related]

  • 4. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR, De Cock F, Collen D.
    Eur J Biochem; 1994 Sep 01; 224(2):567-74. PubMed ID: 7925373
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H.
    J Clin Invest; 1989 Aug 01; 84(2):647-55. PubMed ID: 2503541
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
    Baker MS, Bleakley P, Woodrow GC, Doe WF.
    Cancer Res; 1990 Aug 01; 50(15):4676-84. PubMed ID: 2114945
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
    Schwartz BS.
    J Biol Chem; 1994 Mar 18; 269(11):8319-23. PubMed ID: 7907591
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Transformation-dependent activation of urokinase-type plasminogen activator by a plasmin-independent mechanism: involvement of cell surface membranes.
    Berkenpas MB, Quigley JP.
    Proc Natl Acad Sci U S A; 1991 Sep 01; 88(17):7768-72. PubMed ID: 1652763
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
    Declerck PJ, Lijnen HR, Verstreken M, Moreau H, Collen D.
    Blood; 1990 May 01; 75(9):1794-800. PubMed ID: 1691934
    [Abstract] [Full Text] [Related]

  • 17. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
    Barnathan ES, Kuo A, Rosenfeld L, Karikó K, Leski M, Robbiati F, Nolli ML, Henkin J, Cines DB.
    J Biol Chem; 1990 Feb 15; 265(5):2865-72. PubMed ID: 2154462
    [Abstract] [Full Text] [Related]

  • 18. Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.
    Bizik J, Lizonová A, Stephens RW, Grófová M, Vaheri A.
    Cell Regul; 1990 Nov 15; 1(12):895-905. PubMed ID: 1712633
    [Abstract] [Full Text] [Related]

  • 19. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
    Gyetko MR, Webb AC, Sitrin RG.
    J Immunol; 1988 Oct 15; 141(8):2693-8. PubMed ID: 3139763
    [Abstract] [Full Text] [Related]

  • 20. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
    Meissauer A, Kramer MD, Schirrmacher V, Brunner G.
    Exp Cell Res; 1992 Apr 15; 199(2):179-90. PubMed ID: 1531956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.